요로 결석 관리 기기 시장 : 디바이스 유형별, 치료법별, 디바이스 소재별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Urolithiasis Management Devices Market is projected to grow by USD 1.81 billion at a CAGR of 5.96% by 2032.

Urolithiasis management devices address a high-burden clinical area spanning kidney, ureteral, bladder, and urethral stones. Demand is supported by well-documented risk factors, including dehydration, obesity, diabetes, high dietary sodium intake, low fluid intake, and recurrent stone disease. Epidemiology studies consistently show that kidney stone prevalence has increased over recent decades in many countries, while recurrence remains common, making durable, minimally invasive, and cost-efficient treatment pathways a priority for hospitals and ambulatory surgery centers.

The device landscape includes ureteroscopes, holmium and thulium fiber laser lithotripsy systems, stone retrieval baskets, access sheaths, ureteral stents, nephroscopes, percutaneous nephrolithotomy instruments, and extracorporeal shock wave lithotripsy platforms. Adoption is reinforced by guideline-backed movement toward endoscopic stone treatment, shorter inpatient stays, improved visualization, reduced retreatment needs, and devices that help lower operative time while supporting higher stone-free rates.

Transformative Shifts in the Urolithiasis Devices Landscape

The urolithiasis management devices landscape is being reshaped by the shift from open surgery to minimally invasive endourology. Flexible and single-use ureteroscopes are reducing cross-contamination concerns and repair-related downtime, while high-power laser systems, thulium fiber laser platforms, and advanced fibers improve fragmentation and dusting efficiency. Hospitals are also prioritizing integrated imaging, irrigation control, suction-assisted access, and digital workflow tools that help standardize procedure quality.

A second transformation is occurring in care delivery. More stone procedures are moving into outpatient and same-day settings where device reliability, fast turnover, sterilization efficiency, and predictable supply are essential. Procurement decisions increasingly evaluate total cost of ownership, device reprocessing requirements, surgeon learning curves, service support, and compatibility with existing operating room infrastructure rather than unit price alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence urolithiasis management across diagnosis, procedure planning, and follow-up. AI-enabled imaging tools can support stone detection, measurement, density estimation, segmentation, and automated reporting on CT, which is widely regarded as the reference imaging modality for suspected urinary stones. These capabilities may help clinicians select between surveillance, medical expulsive therapy, ureteroscopy, shock wave lithotripsy, or percutaneous nephrolithotomy.

The cumulative impact of AI will be strongest where it connects imaging, electronic health records, device data, and recurrence-risk models. Predictive analytics can identify patients at higher risk of repeat stones, while automated documentation and operative analytics can improve quality reporting, benchmarking, and procedure planning. Industry leaders should treat AI as a clinical decision-support layer that must be validated, explainable, cybersecurity-ready, and integrated within regulated medical device frameworks.

Key Regional Insights

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in endourology capacity, private hospital networks, and advanced diagnostic imaging. Large patient pools, hot climates in several subregions, urban dietary shifts, and increasing metabolic disease burden support durable demand for ureteroscopic and laser lithotripsy solutions. North America remains a technology-intensive region led by the United States and Canada, where established urology practices, reimbursement access, ambulatory surgery centers, and early adoption of single-use scopes support advanced device utilization.

Europe benefits from guideline-driven care, strong academic urology centers, and broad adoption of minimally invasive stone treatment across Germany, France, Italy, Spain, and the United Kingdom. Latin America is gaining momentum through Brazil and Mexico, though adoption varies with reimbursement, public-sector funding, hospital infrastructure, and specialist access. The Middle East shows strong demand in GCC countries due to high stone prevalence associated with climate, dehydration, and lifestyle risk factors, while Africa presents a long-term access opportunity where affordability, training, equipment maintenance, and infrastructure remain decisive.

Key Group Insights

ASEAN markets are characterized by uneven but rising access to endoscopic urology, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different procurement patterns tied to public-private healthcare mix, specialist distribution, and hospital investment cycles. GCC countries are strategically important because high temperatures, dehydration risk, and sustained investments in advanced hospitals create favorable conditions for lithotripsy systems, ureteroscopes, stents, access sheaths, and procedure-specific disposables.

The European Union offers regulatory harmonization through the Medical Device Regulation, but manufacturers must account for stronger clinical evidence expectations, post-market surveillance, and traceability requirements. BRICS countries represent scale, local manufacturing potential, and price-sensitive tenders, especially in China, India, Brazil, and South Africa, while Russia presents procurement and supply-chain complexity. G7 markets remain innovation leaders with high specialist density, sophisticated reimbursement pathways, and strong procedure standardization, while NATO-aligned countries often benefit from mature procurement systems, training infrastructure, and cross-border clinical collaboration.

Key Country Insights

The United States leads in advanced urolithiasis management device adoption due to high procedural volumes, ambulatory care expansion, broad use of endoscopic stone management, and early uptake of digital ureteroscopy and laser platforms. Canada emphasizes evidence-based procurement and equitable access across provinces, while Mexico is expanding private-sector demand for minimally invasive urology. Brazil is Latin America's largest opportunity, supported by specialist centers, growing hospital investment, and rising demand for ureteroscopy, laser lithotripsy, and percutaneous stone procedures.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong use of guideline-based endoscopic stone management, with Germany particularly important for device quality expectations, hospital purchasing power, and advanced surgical infrastructure. Russia remains relevant but faces procurement complexity and supply-chain constraints. China and India provide high-volume growth potential as hospital infrastructure expands, imaging access improves, and domestic manufacturers scale. Japan, South Korea, and Australia favor advanced, quality-focused technologies supported by sophisticated urology communities, strong clinical training, and well-developed regulatory systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize devices that demonstrate measurable improvements in stone-free rates, operative efficiency, safety, infection control, durability, and lifecycle cost. Product portfolios should combine capital equipment with recurring-use accessories, including laser fibers, baskets, access sheaths, ureteral stents, nephrostomy tools, and irrigation solutions, while offering clear training pathways for urologists, nurses, and operating room teams.

Manufacturers should localize market access strategies by region, strengthen clinical evidence generation, and prepare for stricter post-market data expectations. Partnerships with hospitals, ambulatory surgery centers, and academic urology programs can accelerate adoption and improve procedural consistency. Organizations that integrate AI-ready imaging data, service analytics, cybersecurity controls, and procedure support into compliant platforms will be better positioned for premium differentiation.

Research Methodology

This executive summary is built on secondary research, clinical guideline review, regulatory intelligence, and triangulation of publicly available information from urology associations, government health agencies, peer-reviewed literature, hospital procurement trends, and medical device regulatory bodies. Sources considered include established clinical guidance from the American Urological Association and European Association of Urology, epidemiological literature on stone disease incidence and recurrence, and regulatory frameworks such as U.S. FDA requirements and the EU Medical Device Regulation.

The methodology evaluates demand drivers, technology shifts, care settings, competitive positioning, regional access conditions, reimbursement indicators, and compliance requirements. Insights are validated through cross-comparison of clinical, commercial, and policy evidence to ensure that conclusions remain data-backed, practical, and relevant for decision-makers in urolithiasis management devices.

Conclusion

The urolithiasis management devices market is moving toward minimally invasive, digitally enabled, and evidence-driven care. Rising stone burden, recurring disease, and growing demand for efficient outpatient procedures continue to support adoption of ureteroscopy, laser lithotripsy, stone retrieval tools, stents, percutaneous nephrolithotomy instruments, and related endourology platforms.

Competitive advantage will depend on clinical performance, reliability, training support, regulatory readiness, infection prevention, service quality, and total cost of ownership. Companies that align product innovation with regional access realities and AI-enabled clinical workflows can capture sustainable growth while improving patient outcomes across global stone disease care pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urolithiasis Management Devices Market, by Device Type

• 7.1. Guidewires
• 7.2. Lithotripters
• 7.3. Stents
• 7.4. Ureteroscopes

8. Urolithiasis Management Devices Market, by Treatment Type

• 8.1. Extracorporeal Shock Wave Lithotripsy
• 8.2. Intracorporeal Lithotripsy
• 8.3. Percutaneous Nephrolithotomy

9. Urolithiasis Management Devices Market, by Device Material

• 9.1. Metal-Based Devices
• 9.2. Polymer-Based Devices

10. Urolithiasis Management Devices Market, by Application

• 10.1. Bladder Stones
• 10.2. Kidney Stones
• 10.3. Ureteral Stones

11. Urolithiasis Management Devices Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Urolithiasis Management Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Urolithiasis Management Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Urolithiasis Management Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Advanced MedTech Holdings
• 16.2. AKSM, Ltd.
• 16.3. Avvio Medical, Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Boston Scientific Corporation
• 16.6. Calyxo Inc.
• 16.7. Coloplast A/S
• 16.8. Cook Group Incorporated
• 16.9. DirexGroup
• 16.10. Dornier MedTech GmbH
• 16.11. Dyne Medical Group Inc.
• 16.12. E.M.S. Electro Medical Systems S.A.
• 16.13. EDAP TMS SA
• 16.14. Elmed Lithotripsy Systems
• 16.15. EndoTheia, Inc.
• 16.16. Karl Storz GmbH & Co. KG
• 16.17. Nissha Medical Technologies
• 16.18. Olympus Corporation
• 16.19. Quanta System S.p.A.
• 16.20. Richard Wolf GmbH
• 16.21. Siemens Healthineers
• 16.22. SonoMotion
• 16.23. Teleflex Incorporated